Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
| Status: | Archived |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2008 |
| End Date: | June 2011 |
A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors
AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with
the protocol increasing doses of AT13387 are given to patients with advanced cancer who do
not have alternative treatment options. The preferred dose of AT13387 will be identified
according to the side effects experienced at different dose levels.
Increasing doses of AT13387 will be administered to groups of 3 to 6 patients at each dose
level. The pharmacokinetic profile of AT13387 following a one hour intravenous infusion will
be determined and the effect of AT13387 on predefined biomarkers in blood plasma and
circulating white blood cells will be established. Patients will be closely monitored for
the development of side effects which would preclude further dose escalation.
We found this trial at
4
sites
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials